Recent news on Quadramet

Cytogen Reports First Quarter 2007 Financial Results  -  May 10, 2007
PharmaLive.com (press release),For the first quarter of 2007, Cytogen's product revenues were comprised of sales of QUADRAMET(R) (samarium Sm-153 lexidronam injection) and PROSTASCINT(R)

Preclinical Data on Cytogen's Technology to be Reported at the ...  -  Mar 29, 2007
Nanotechnology News (press release)QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone. PROSTASCINT is a PSMA-targeting monoclonal antibody-based

New Clinical Data for Cytogen’s QUADRAMET and PROSTASCINT to be ...  -  27 Mar 2007
Business Wire (press release),The data will include various Phase 1 clinical results for QUADRAMET® (samarium Sm-153 lexidronam injection) in combination settings for the treatment of

Phase II Clinical Trial of Cytogens QUADRAMET with PSA-TRICOM ...  -  Mar 5, 2007
Cancer Focus,The study, "Use of Samarium-153 (QUADRAMET) to modulate phenotype and enhance killing of tumor cells" demonstrated that exposure to QUADRAMET resulted in

Cytogen Announces Initiation of NCI-Sponsored Phase 2 Clinical ...  -  Mar 1, 2007
Business Wire (press release),QUADRAMET is a targeted radiopharmaceutical that is approved for treating pain arising from cancer that has spread to the bone. PSA-TRICOM is a targeted

Cytogen Reports Fourth Quarter and Full Year 2006 Financial Results  -  Mar 1, 2007
PharmaLive.com (press release),Mr. Becker added: "Second, we have continued to advance our data-driven strategy to unlock the market potential of QUADRAMET and PROSTASCINT.

Cytogen initiates prostate cancer study  -  Mar 1, 2007
Pharmaceutical Business ReviewCytogen Corporation has initiated a phase II study to evaluate Quadramet in combination with the therapeutic vaccine, PSA-TRICOM for patients with prostate

Biotech Day In Review: Amgen Hit with SEC Investigation  -  Mar 1, 2007
Seeking Alpha,Cytogen (CYTO) said the National Cancer Institute began a Phase II trial of Quadramet, administered with the therapeutic vaccine PSA-TRICOM,

Cytogen Announces Initiation of Phase 1 Trial for Radiolabeled ...  -  Feb 27, 2007
NJBIZ,QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based

Pet care leaps forward  -  Mar 24, 2007
Columbia Daily Tribune,In the 1980s and 1990s, animal cancer treatment at the veterinary school helped lead to an MU breakthrough that resulted in the drug Quadramet,

Market Report -- In Play (WIRES)  -  Mar 1, 2007
MSN MoneyCytogen (CYTO) announces that the National Cancer Institute has initiated a randomized Phase 2 study to evaluate Quadramet in combination with the NIH's

New Clinical Data for PROSTASCINT(R) and QUADRAMET(R) in Prostate ...  -  25 Feb 2007
FinanzNachrichten.de,The two QUADRAMET-related presentations were focused on the safety and efficacy of QUADRAMET in combination with taxane-based chemotherapy for prostate

Cytogen to Present at BIO CEO and Investor Conference  -  Feb 7, 2007
PharmaLive.com (press release),QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based

Expanded Role for Cytogen's PROSTASCINT(R) Incorporated Into NCCN ...  -  Jan 4, 2007
American Digital Networks (press release),QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based

Quadramet relieves cancer pain  -  Dec 18, 2006
United Press International18 (UPI) -- Injections of Quadramet cut pain by up to 80 percent in patients with prostate or breast cancer that spread to the bone, says a US study.

Data from Phase 1 Dose Escalation Study of QUADRAMET(R) and ...  -  Dec 11, 2006
Drug Newswire (press release),Both arms use escalating doses of QUADRAMET (0.25 mCi/kg, 0.5 mCi/kg, and 1.0 mCi/kg). The standard approved dose of QUADRAMET for palliation of bone pain

Data From Phase 1 Dose Escalation Study Of QUADRAMET(R) And ...  -  Dec 12, 2006
Medical News Today (press release),Cytogen Corporation (Nasdaq: CYTO) reported the presentation of updated data from an ongoing Phase 1 dose escalation study evaluating QUADRAMET(R) (samarium

Data from Phase 1 Dose Escalation Study of QUADRAMET(R) and ...  -  Dec 11, 2006
PR Newswire (press release),Novel combination regimen of QUADRAMET with the protease inhibitor, bortezomib, well-tolerated with patients receiving up to four doses;

American Cancer Society Journal Article Reports New Data Regarding ...  -  Dec 18, 2006
PharmaLive.com (press release),QUADRAMET, a targeted radiopharmaceutical, is approved for treating pain from cancer that has spread to the bone. The article, "Safety and efficacy of

American Cancer Society Journal Article Reports New Data Regarding ...  -  Dec 18, 2006
Business Wire (press release),A recent study has found repeated dosing of QUADRAMET to be a safe and effective treatment option for patients with painful bone metastases.

Market Report -- In Play (CYTO)  -  Dec 18, 2006
MSN MoneyCytogen says new data from Phase 4 study of Quadramet published in the early online view of the American Cancer Society's journal Cancer Co announces that

Cytogen Receives Patent Covering Oral Drug Delivery Agents  -  Nov 28, 2006
Drug Newswire (press release),QUADRAMET is approved for the treatment of pain in patients whose cancer has spread to the bone, PROSTASCINT is a PSMA-targeting monoclonal antibody-based

Sección internacional  -  Dec 11, 2006
Bolsamania.com,...(PRN) - Data from Phase 1 Dose Escalation Study of QUADRAMET(R) and Bortezomib in Patients with Relapsed Multiple Myeloma Presented at the American Society

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional